CAMP Continuation Study/Phse 2 (CAMPCS/2)

待检验的主要假设是，5-12岁儿童哮喘吸入性皮质类固醇治疗3.5-5年是否在最大限度地实现肺生长方面具有长期获益。这将通过继续随访最初的儿童哮喘管理计划（CAMP）队列来实现，直到大多数人达到他们的最大成人身高。阿尔伯克基研究中心同意继续随访并获得其队列中的必要测量值，以实现华盛顿大学圣路易斯分校科学方案中描述的所有特定目标。121例患者最初在阿尔伯克基研究中心接受随机化，我们目前有100例患者入组CAMPCS队列 随访研究。截至2002年8月，在目前入组CAMPCS的患者中，我们成功完成了96%的所有肺功能测量、97%的所有线性生长测量和93%的所有乙酰甲胆碱激发测量。所有最初的队列，其中包括41%的少数民族和40%的女性有资格参加，我们将尝试联系他们所有人，即使是那些目前没有参加CAMPCS。

The primary hypothesis to be tested is whether 3.5-5 years treatment of asthma in children 5-12 years of age with inhaled corticosteroids has a long-term benefit in allowing maximum attainment of lung growth. This will be achieved by continued followup of the original Childhood Asthma Management Program (CAMP) cohort until the majority have reached their maximal adult height. The Albuquerque site agrees to continue to follow and obtain the necessary measurements in their cohort to fulfill all of the specific aims as described in the Washington University, St. Louis scientific protocol. One hundred twenty-one patients were initially randomized at the Albuquerque site and we currently have 100 patients enrolled in the CAMPCS cohort followup study. Of those patients currently enrolled in CAMPCS we have successfully completed 96% of all pulmonary function measures, 97% of all linear growth measures and 93% of all methacholine challenge measures up to August 2002. All of the original cohort which consisted of 41% minorities and 40% females is eligible to participate and we will attempt to contact them all, even those not currently enrolled in CAMPCS.